An Early Phase 1 interventional study of PF-04457845 and Placebo in Fear Conditioning, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-11.
Sponsored by Yale University · Early Phase 1, Interventional, and Other
The purpose of this double blind, randomized, controlled, proof-of-concept study is to test the effects of cannabinoid receptor augmentation on the facilitation of fear conditioning. On three days over not more than two weeks, subjects will be trained to associate cues with two different stimuli, then this association will be extinguished. Cannabinoid receptor stimulation will be accomplished indirectly by harnessing the brain's capacity to endocannabinoids through the administration of an enzyme (FAAH inhibitor) that prevents degradation of anandamide. Subjects will receive placebo or the FAAH-inhibitor PF-04457845. Some details of this study have not been disclosed to preserve the study design.
Yale University is the lead sponsor of 1,724 studies on the registry; 298 are open to participants now.
Of its 210 completed or terminated interventional studies of FDA-regulated products, 126 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Acquisition of conditioning Administration of drug Extinction of conditioning
Drug: PF-04457845 · Drug: Placebo
Placebo
Drug: PF-04457845 · Drug: Placebo
Acquisition of conditioning Administration of drug Extinction of conditioning
Acquisition of conditioning Administration of placebo Extinction of conditioning
Galvanic skin response
Measure of sympathetic autonomic activation
Time frame: Test days #1, #2, and #3, on average a week
Cortisol levels measured in blood
Salivary b-amylase and serum cortisol levels will be assessed as neurochemical measures of stress response.
Time frame: Test days #1, #2, and #3, on average a week
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yale University